Managing the Development Process and Strengthening the Pipeline Toward Launch
First written in FY2023. 4 of 7 entries say "Advanced", first in FY2024-Q3. Latest entry: FY2027-H1.
The whole theme swung hardest in 2019: 1 of 10 companies on the "Worse" side.
9 other companies' latest entry also says "Advanced".
- FY2027-H1AdvancedAnnual report
「During the interim accounting period, the Company actively pursued R&D activities to expand its pipeline through its 2 internal and external program streams.」
Pipeline expansion through internal and external programs continued, progressing to the acquisition, evaluation and patent filing for more than 100 novel compounds, new university collaborations and the introduction of additional external seeds. - FY2026-H1RestatedAnnual report
「During the interim accounting period, the Company actively pursued R&D activities to expand its pipeline through its 2 internal and external program streams.」
The Company continues R&D activities to expand the pipeline through internal and external programs. - FY2025RestatedAnnual report
「Because the Company is currently in the R&D stage, it has not established objective indicators for assessing progress toward management targets. Nevertheless, it is pursuing its business activities with the enhancement of the development process and pipeline as important objectives.」
The Company continues to state that it has not established objective indicators, while treating development-process management and pipeline enhancement as important objectives. - FY2025-H1AdvancedAnnual report
「The Company’s clinical pipeline increased from 1 to 3 programs in the previous fiscal year. During the interim accounting period (1 March 2024 to 31 August 2024), continued development progress and further expansion through internal and external sources resulted in the addition of 1 new preclinical program.」
After the clinical pipeline increased from 1 to 3 programs, 1 additional preclinical program was added, demonstrating concrete progress in expansion through internal and external sources. - FY2025-Q1AdvancedAnnual report
「During the first quarter, the Company actively pursued R&D activities to expand its pipeline through its 2 internal and external program streams.」
The Company advanced pipeline expansion through internal and external programs, obtaining and evaluating promising internal candidates and ultimately securing an exclusive license for TMS-010 from Hokkaido University. - FY2024-Q3AdvancedAnnual report
「The Company actively pursued R&D activities to expand its pipeline along 2 axes: internal programs and external programs.」
The Company pursued pipeline expansion through internal and external programs, advancing candidate evaluation to Phase 2, signing a three-party university research agreement and discussing next steps after completing evaluation. - FY2023First statedAnnual report
「Aiming to launch treatments as soon as possible, the Company considers managing the process from research and development through launch to be its most important management priority for the time being. Strengthening the pipeline is also essential to stabilizing management and increasing corporate value.」
The Company identifies development-process management from research through launch and pipeline strengthening as key near-term management objectives.